JP2001524809A - 神経系疾患の治療に使用するための遺伝薬理学的方法 - Google Patents
神経系疾患の治療に使用するための遺伝薬理学的方法Info
- Publication number
- JP2001524809A JP2001524809A JP52750798A JP52750798A JP2001524809A JP 2001524809 A JP2001524809 A JP 2001524809A JP 52750798 A JP52750798 A JP 52750798A JP 52750798 A JP52750798 A JP 52750798A JP 2001524809 A JP2001524809 A JP 2001524809A
- Authority
- JP
- Japan
- Prior art keywords
- patient
- disease
- patients
- diagnosed
- apoe4
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Electrotherapy Devices (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 下記の段階を含む、神経疾患であると診断された患者の予後計画を作成する 方法: a)該疾患であることがすでに診断されている患者を同定する段階、 b)該患者のアポE対立遺伝子負荷を判定する段階、および c)段階b)で得られたデータを予後計画に変換する段階であって、該予後計 画が薬物の効果および患者の結果を予測することを含む段階。 2. 下記の段階を含む、ADであると診断された患者の予後計画を作成する方法: a)該疾患であることがすでに診断されている患者を同定する段階、 b)該患者のアポE対立遺伝子負荷を判定する段階、および c)段階b)およびc)で得られたデータを予後計画に変換する段階であって 、該予後計画が薬物の効果および患者の結果を予測することを含む段階。 3. 患者プロフィールを入手する段階をさらに含む、請求項1または請求項2記 載の方法。 4. 患者が、プリオン病、発育期神経系異常、老化性神経系異常、神経系損傷、 昏睡、神経系感染症、栄養欠乏および循環器系損傷からなる群より選択される疾 患であると診断される、請求項1記載の方法。 5. プリオン病がクロイツフェルト-ヤコブ病である、請求項4記載の方法。 6. 患者がアミノ酸代謝に先天的欠陥を有すると診断される、請求項4記載の方 法。 7. 欠陥が、アルギニノコハク酸尿症、シスタチオニン尿症、ヒスチジン血症、 ホモシスチン尿症、アンモニア過剰血症、フェニルケトン尿症およびチロシン血 症からなる群より選択される、請求項6記載の方法。 8. 患者が脆弱X染色体症候群であると診断される、請求項4記載の方法。 9. 患者が、神経線維腫症、ハンチントン病、うつ病、筋萎縮性側索硬化症、多 発性硬化症、卒中、パーキンソン病および多発梗塞性痴呆からなる群より選択さ れる疾患であると診断される、請求項4記載の方法。 10. 疾患がアルツハイマー病である、請求項9記載の方法。 11. 患者プロフィールが該患者の性別判定を含む、請求項3記載の方法。 12. 患者プロフィールが該患者の遺伝子型を含む、請求項3記載の方法。 13. 遺伝子型がプレセニリン遺伝子型である、請求項12記載の方法。 14. 遺伝子型がアポリポタンパク質C1遺伝子型である、請求項12記載の方法。 15. 下記の段階を含む、非AD神経疾患を治療する薬物の臨床試験の対象となる 非AD患者を同定するための方法: a)該非AD神経疾患であることがすでに診断されている患者を同定する段階 、 b)該患者のアポE対立遺伝子負荷を判定する段階、および c)段階b)で得られたデータを予後計画に変換する段階であって、該予後計 画は、該患者がコリン様薬臨床試験の候補であるか、または非コリン様薬臨床試 験の候補であるかを示す段階。 16. 下記の段階を含む、ADを治療する薬物の臨床試験の対象となるAD患者を同 定するための方法: a)該ADであることがすでに診断されている患者を同定する段階、 b)該患者のアポE対立遺伝子負荷を判定する段階、および c)段階b)で得られたデータを予後計画に変換する段階であって、該予後計 画は、該患者がコリン様薬臨床試験の候補であるか、または非コリン様薬臨床試 験の候補であるかを示す段階。 17. 下記の段階を含む、ヒトがコリン様認識増強剤に応答するかどうかを判定 するための方法: a)該患者の患者プロフィールを入手する段階、 b)該ヒトのアポE対立遺伝子負荷を判定する段階、および c)該コリン様薬のレシピエントとしてアポE2またはアポE3対立遺伝子の少 なくとも一方を有するヒトを選択する段階。 18. 患者プロフィールを予後計画に変換するための手段を含む、遺伝薬理学的 解析を実施するためのキット。 19. 変換段階を実施するための手段を有する、請求項15記載のキット。 20. 患者プロフィールデータをコンパイルするための手段を有する、請求項15 記載のキット。 21. 患者が卒中であると診断される、請求項9記載の方法。 22. 患者がパーキンソン病であると診断される、請求項9記載の方法。 23. 患者が、多発性硬化症であると診断される、請求項9記載の方法。 24. 患者がBChE-K対立遺伝子を有すると判定される、請求項1または2記載の方 法。 25. 患者が、ピック病、レーヴィ小体病および神経線維腫症からなる群より選 択される疾患であると診断される、請求項4記載の方法。 26. 患者のBChE-K対立遺伝子状態を判定する段階をさらに含む、請求項15記載 の方法。 27. 患者のBChE-K対立遺伝子状態を判定する段階をさらに含む、請求項16記載 の方法。 28. 患者のBChE-K対立遺伝子状態を判定する段階をさらに含む、請求項17記載 の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/766,975 US6022683A (en) | 1996-12-16 | 1996-12-16 | Methods for assessing the prognosis of a patient with a neurodegenerative disease |
US08/766,975 | 1996-12-16 | ||
PCT/IB1997/001648 WO1998027227A2 (en) | 1996-12-16 | 1997-12-16 | Pharmacogenetic methods for use in the treatment of nervous system diseases |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009113073A Division JP5202429B2 (ja) | 1996-12-16 | 2009-05-07 | 神経系疾患の治療に使用するための遺伝薬理学的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001524809A true JP2001524809A (ja) | 2001-12-04 |
JP2001524809A5 JP2001524809A5 (ja) | 2005-08-11 |
Family
ID=25078098
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52750798A Withdrawn JP2001524809A (ja) | 1996-12-16 | 1997-12-16 | 神経系疾患の治療に使用するための遺伝薬理学的方法 |
JP2009113073A Expired - Fee Related JP5202429B2 (ja) | 1996-12-16 | 2009-05-07 | 神経系疾患の治療に使用するための遺伝薬理学的方法 |
JP2012117411A Pending JP2012152229A (ja) | 1996-12-16 | 2012-05-23 | 神経系疾患の治療に使用するための遺伝薬理学的方法 |
JP2012274378A Pending JP2013059347A (ja) | 1996-12-16 | 2012-12-17 | 神経系疾患の治療に使用するための遺伝薬理学的方法 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009113073A Expired - Fee Related JP5202429B2 (ja) | 1996-12-16 | 2009-05-07 | 神経系疾患の治療に使用するための遺伝薬理学的方法 |
JP2012117411A Pending JP2012152229A (ja) | 1996-12-16 | 2012-05-23 | 神経系疾患の治療に使用するための遺伝薬理学的方法 |
JP2012274378A Pending JP2013059347A (ja) | 1996-12-16 | 2012-12-17 | 神経系疾患の治療に使用するための遺伝薬理学的方法 |
Country Status (8)
Country | Link |
---|---|
US (2) | US6022683A (ja) |
EP (2) | EP0948647B1 (ja) |
JP (4) | JP2001524809A (ja) |
AT (1) | ATE269978T1 (ja) |
AU (2) | AU745073B2 (ja) |
CA (2) | CA2275404C (ja) |
DE (2) | DE69729654T2 (ja) |
WO (2) | WO1998027226A2 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014519076A (ja) * | 2011-04-28 | 2014-08-07 | ゼネラル・エレクトリック・カンパニイ | 薬理データの全体論的分析および可視化を用いて薬効を評価するための装置、システム、および方法 |
US10658073B2 (en) | 2014-08-15 | 2020-05-19 | QIAGEN Redwood City, Inc. | Methods and systems for interpretation and reporting of sequence-based genetic tests using pooled allele statistics |
US10665328B2 (en) | 2014-06-30 | 2020-05-26 | QIAGEN Redwood City, Inc. | Methods and systems for interpretation and reporting of sequence-based genetic tests |
WO2020091375A3 (ko) * | 2018-10-29 | 2020-06-25 | 고려대학교 산학협력단 | 항우울제 추천 방법 및 시스템 |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6022683A (en) * | 1996-12-16 | 2000-02-08 | Nova Molecular Inc. | Methods for assessing the prognosis of a patient with a neurodegenerative disease |
US6489095B2 (en) | 1998-06-15 | 2002-12-03 | Mitokor | Diagnostic method based on quantification of extramitochondrial DNA |
US6441149B1 (en) | 1998-06-15 | 2002-08-27 | Mitokor | Diagnostic method based on quantification of extramitochondrial DNA |
US6218117B1 (en) | 1998-06-15 | 2001-04-17 | Mitokor | Compositions and methods for identifying agents that quantitatively alter detectable extramitochondrial DNA:mitochondrial DNA ratios |
WO1999066072A2 (en) * | 1998-06-16 | 1999-12-23 | Nova Molecular, Inc. | Methods for treating a neurological disease by determining bche genotype |
WO2000020634A1 (en) | 1998-10-01 | 2000-04-13 | Nova Molecular, Inc. | Methods for treating or identifying a subject at risk for a neurological disease by determining the presence of a variant gpiiia and/or variant gpiib allele |
WO2000070340A2 (en) * | 1999-05-14 | 2000-11-23 | Karolinska Innovations Ab | Materials and methods relating to disease diagnosis |
US7058517B1 (en) | 1999-06-25 | 2006-06-06 | Genaissance Pharmaceuticals, Inc. | Methods for obtaining and using haplotype data |
CA2369485A1 (en) * | 1999-06-25 | 2001-01-04 | Genaissance Pharmaceuticals, Inc. | Methods for obtaining and using haplotype data |
US6692916B2 (en) * | 1999-06-28 | 2004-02-17 | Source Precision Medicine, Inc. | Systems and methods for characterizing a biological condition or agent using precision gene expression profiles |
US6960439B2 (en) * | 1999-06-28 | 2005-11-01 | Source Precision Medicine, Inc. | Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles |
US6573049B1 (en) | 1999-07-26 | 2003-06-03 | Nuvelo, Inc. | Genotyping of the paraoxonase 1 gene for prognosing, diagnosing, and treating a disease |
US6896881B1 (en) | 1999-09-24 | 2005-05-24 | Mayo Foundation For Medical Education And Research | Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family |
WO2001069261A2 (en) * | 2000-03-15 | 2001-09-20 | Oxford Glycosciences (Uk) Ltd. | Proteins, genes and their use for diagnosis and treatment of vascular dementia |
DK1292294T3 (da) * | 2000-05-01 | 2009-06-22 | Accera Inc | Anvendelse af mediumkæde-triglycerider til behandling og forebyggelse af Alzheimers sygdom |
US20070179197A1 (en) * | 2000-05-01 | 2007-08-02 | Accera, Inc. | Compositions and methods for improving or preserving brain function |
US20080009467A1 (en) * | 2000-05-01 | 2008-01-10 | Accera, Inc. | Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism |
US6835750B1 (en) | 2000-05-01 | 2004-12-28 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
US6931326B1 (en) | 2000-06-26 | 2005-08-16 | Genaissance Pharmaceuticals, Inc. | Methods for obtaining and using haplotype data |
US20030105082A1 (en) * | 2001-12-03 | 2003-06-05 | Murphy Greer Marechal | Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4 |
US6399310B1 (en) | 2001-02-12 | 2002-06-04 | Akzo Nobel N.V. | Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4 |
WO2002064735A2 (en) * | 2001-02-12 | 2002-08-22 | Akzo Nobel N.V. | Methods for improving the treatment of major depression by genotyping for the gene for apolipoproteine e4 |
GB0106051D0 (en) * | 2001-03-12 | 2001-05-02 | Isis Innovation | Diagnostic screens for alzheimer's disease |
US20030104453A1 (en) * | 2001-11-06 | 2003-06-05 | David Pickar | System for pharmacogenetics of adverse drug events |
CA2466502A1 (en) * | 2001-11-09 | 2003-05-15 | Source Precision Medicine, Inc. | Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles |
US20030224446A1 (en) * | 2001-12-20 | 2003-12-04 | Harry G. Jean | Method of predicting cytokine response to tissue injury |
US20040267458A1 (en) * | 2001-12-21 | 2004-12-30 | Judson Richard S. | Methods for obtaining and using haplotype data |
AU2003216186A1 (en) * | 2002-02-14 | 2003-09-04 | Medavante, Inc. | System and method for facilitating candidate and subject participation in clinical trial studies |
US7432355B2 (en) * | 2002-08-09 | 2008-10-07 | The J. David Gladstone Institutes | Apolipoprotein E stable folding intermediate and methods of use thereof |
US8688385B2 (en) | 2003-02-20 | 2014-04-01 | Mayo Foundation For Medical Education And Research | Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype |
AU2004248302B2 (en) * | 2003-06-19 | 2009-07-30 | Merck Serono Sa | Use of prion conversion modulating agents |
US20050038692A1 (en) * | 2003-08-14 | 2005-02-17 | Kane John Michael | System and method for facilitating centralized candidate selection and monitoring subject participation in clinical trial studies |
ZA200605829B (en) * | 2004-01-16 | 2007-11-28 | Disease Man Services Plc | Disease Management System |
AU2005263577C1 (en) | 2004-07-16 | 2010-08-26 | Proteosys Ag | Muscarinic antagonists with PARP and SiR modulating activity as cytoprotective agents |
US20060252775A1 (en) * | 2005-05-03 | 2006-11-09 | Henderson Samuel T | Methods for reducing levels of disease associated proteins |
US20070135376A1 (en) * | 2005-06-20 | 2007-06-14 | Accera, Inc. | Method to reduce oxidative damage and improve mitochondrial efficiency |
JP2009517186A (ja) * | 2005-11-29 | 2009-04-30 | チルドレンズ ホスピタル メディカル センター | 薬物選択及び投薬の最適化及び個別化 |
HUE035852T2 (en) | 2006-04-03 | 2018-05-28 | Accera Inc | Use of ketogen compounds to treat memory decline |
US20080126118A1 (en) * | 2006-11-24 | 2008-05-29 | General Electric Company, A New York Corporation | Systems, methods and apparatus for a network application framework system |
TWI362012B (en) * | 2007-07-23 | 2012-04-11 | System of providing hygienic education information and method thereof | |
ES2556535T3 (es) | 2007-07-31 | 2016-01-18 | Accera, Inc. | Uso de ensayo genómico y compuestos cetogénicos para tratamiento de una función cognitiva reducida |
US20090198504A1 (en) * | 2008-02-05 | 2009-08-06 | Medavante, Inc. | Rater resource allocation systems and methods |
CN102105071A (zh) * | 2008-07-03 | 2011-06-22 | 艾克塞拉公司 | 用于治疗神经性障碍的乙酰乙酸的单甘油酯及其衍生物 |
US8105809B2 (en) * | 2008-07-03 | 2012-01-31 | Accera, Inc. | Enzymatic synthesis of acetoacetate esters and derivatives |
EP2379080A1 (en) | 2009-01-13 | 2011-10-26 | ProteoSys AG | Pirenzepine as otoprotective agent |
EP2360280A1 (en) * | 2010-02-24 | 2011-08-24 | Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol | Genetic marker for the diagnosis of dementia with Lewy bodies |
US20130080182A1 (en) * | 2011-09-26 | 2013-03-28 | Athleticode Inc. | Methods For Using DNA Testing To Screen For Genotypes Relevant To Athleticism, Health And Risk Of Injury |
RU2467680C1 (ru) * | 2011-10-04 | 2012-11-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения и социального развития Российской Федерации | Способ прогнозирования эффективности лечения больных ишемическим инсультом |
EP3628315A1 (en) | 2018-09-28 | 2020-04-01 | Université de Caen Normandie | Combination of acetylcholinesterase inhibitor and 5-ht4 receptor agonist as neuroprotective agent in the treatment of neurodegenerative diseases |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3265577B2 (ja) * | 1992-10-13 | 2002-03-11 | デューク・ユニバーシティ | アポリポ蛋白eの4型イソ型の測定法 |
CA2111503A1 (en) * | 1993-12-15 | 1995-06-16 | Mcgill University | Apolipoprotein e polymorphism and alzheimer's disease |
FR2716894B1 (fr) * | 1994-03-07 | 1996-05-24 | Pasteur Institut | Marqueurs génétiques utilisés conjointement pour le diagnostic de la maladie d'Alzheimer, méthode et kit de diagnostic. |
GB9408465D0 (en) * | 1994-04-27 | 1994-06-22 | Univ Mcgill | Apolipoprotein e polymorphism & treatment of alzheimer's disease |
GB9415073D0 (en) * | 1994-06-27 | 1994-09-14 | Smithkline Beecham Plc | Novel method |
GB9414624D0 (en) * | 1994-07-20 | 1994-09-07 | Smithkline Beecham Plc | Novel method |
US6022683A (en) * | 1996-12-16 | 2000-02-08 | Nova Molecular Inc. | Methods for assessing the prognosis of a patient with a neurodegenerative disease |
-
1996
- 1996-12-16 US US08/766,975 patent/US6022683A/en not_active Expired - Lifetime
-
1997
- 1997-12-16 JP JP52750798A patent/JP2001524809A/ja not_active Withdrawn
- 1997-12-16 EP EP97952129A patent/EP0948647B1/en not_active Expired - Lifetime
- 1997-12-16 AT AT97952129T patent/ATE269978T1/de not_active IP Right Cessation
- 1997-12-16 CA CA2275404A patent/CA2275404C/en not_active Expired - Fee Related
- 1997-12-16 EP EP97953011A patent/EP0946753B1/en not_active Expired - Lifetime
- 1997-12-16 WO PCT/IB1997/001641 patent/WO1998027226A2/en active IP Right Grant
- 1997-12-16 WO PCT/IB1997/001648 patent/WO1998027227A2/en active IP Right Grant
- 1997-12-16 AU AU56757/98A patent/AU745073B2/en not_active Ceased
- 1997-12-16 CA CA002275504A patent/CA2275504C/en not_active Expired - Fee Related
- 1997-12-16 AU AU55717/98A patent/AU5571798A/en not_active Withdrawn
- 1997-12-16 DE DE69729654T patent/DE69729654T2/de not_active Expired - Lifetime
- 1997-12-16 DE DE69729473T patent/DE69729473T2/de not_active Expired - Lifetime
-
2000
- 2000-02-08 US US09/500,162 patent/US7001736B1/en not_active Expired - Fee Related
-
2009
- 2009-05-07 JP JP2009113073A patent/JP5202429B2/ja not_active Expired - Fee Related
-
2012
- 2012-05-23 JP JP2012117411A patent/JP2012152229A/ja active Pending
- 2012-12-17 JP JP2012274378A patent/JP2013059347A/ja active Pending
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014519076A (ja) * | 2011-04-28 | 2014-08-07 | ゼネラル・エレクトリック・カンパニイ | 薬理データの全体論的分析および可視化を用いて薬効を評価するための装置、システム、および方法 |
US10665328B2 (en) | 2014-06-30 | 2020-05-26 | QIAGEN Redwood City, Inc. | Methods and systems for interpretation and reporting of sequence-based genetic tests |
US10658073B2 (en) | 2014-08-15 | 2020-05-19 | QIAGEN Redwood City, Inc. | Methods and systems for interpretation and reporting of sequence-based genetic tests using pooled allele statistics |
WO2020091375A3 (ko) * | 2018-10-29 | 2020-06-25 | 고려대학교 산학협력단 | 항우울제 추천 방법 및 시스템 |
Also Published As
Publication number | Publication date |
---|---|
EP0946753B1 (en) | 2004-06-09 |
JP2009213482A (ja) | 2009-09-24 |
CA2275504A1 (en) | 1998-06-25 |
WO1998027227A3 (en) | 1998-08-27 |
EP0948647A1 (en) | 1999-10-13 |
AU5675798A (en) | 1998-07-15 |
US6022683A (en) | 2000-02-08 |
WO1998027226A2 (en) | 1998-06-25 |
JP2013059347A (ja) | 2013-04-04 |
CA2275404C (en) | 2011-02-08 |
DE69729654D1 (de) | 2004-07-29 |
DE69729473T2 (de) | 2005-06-09 |
EP0948647B1 (en) | 2004-06-23 |
EP0946753A2 (en) | 1999-10-06 |
JP2012152229A (ja) | 2012-08-16 |
CA2275504C (en) | 2009-09-22 |
CA2275404A1 (en) | 1998-06-25 |
AU5571798A (en) | 1998-07-15 |
WO1998027226A3 (en) | 1998-08-20 |
AU745073B2 (en) | 2002-03-14 |
DE69729473D1 (de) | 2004-07-15 |
WO1998027227A2 (en) | 1998-06-25 |
DE69729654T2 (de) | 2005-07-21 |
JP5202429B2 (ja) | 2013-06-05 |
ATE269978T1 (de) | 2004-07-15 |
US7001736B1 (en) | 2006-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5202429B2 (ja) | 神経系疾患の治療に使用するための遺伝薬理学的方法 | |
JP3285585B2 (ja) | アポリポ蛋白質eの多形性およびアルツハイマー病の治療 | |
Tsai et al. | Apolipoprotein E: risk factor for Alzheimer disease. | |
Blacker et al. | ApoE-4 and age at onset of Alzheimer's disease: the NIMH genetics initiative | |
EP2449134B1 (en) | Diagnosis and treatment of alzheimer's disease | |
Xiao et al. | Association studies of several cholesterol-related genes (ABCA1, CETP and LIPC) with serum lipids and risk of Alzheimer’s disease | |
Dobson-Stone et al. | Frontotemporal dementia–amyotrophic lateral sclerosis syndrome locus on chromosome 16p12. 1–q12. 2: genetic, clinical and neuropathological analysis | |
EP1529116B1 (en) | Method for predicting the responsiveness to treatment with rivastigmine based on the ApoE genotyp of dementia patients | |
Li et al. | CYP46A1 and the APOEε4 allele polymorphisms correlate with the risk of Alzheimer’s disease | |
Neugroschl et al. | Biological markers in Alzheimer disease | |
US7049078B2 (en) | Apolipoprotein E polymorphism and treatment of alzheimer's disease | |
Reitz et al. | Use of genetic variation as biomarkers for Alzheimer's disease | |
EP1074634A1 (en) | Method for the diagnosis or the prognosis of Alzheimer disease therapeutical composition for preventing or treating Alzheimer disease | |
US20140088035A1 (en) | Treating schizophrenia | |
Helisalmi et al. | The leucine (7)-to-proline (7) polymorphism in the signal peptide of neuropeptide Y is not associated with Alzheimer's disease or the link apolipoprotein E | |
AU733237B2 (en) | Use of Apolipoprotein polymorphism E in the treatment of Alzheimer's disease | |
Moreno-Grau | The genetic basis of alzheimer's disease and its related endophenotypes | |
US20140142150A1 (en) | Treating neuropsychiatric disorders | |
Knopman | Department of Neurology, Mayo Clinic, Rochester, MN, USA | |
Miller | Genetic Susceptibility in Alzheimer’s Disease and the Role of Lipid Metabolism | |
NZ500375A (en) | A genotyping survey for characterising the presence of E2 and E3 allele or the absence of apolipoprotein E4 allele for determining the level of treatment medication for Alzheimer's patients |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041215 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041215 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080325 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20080613 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080625 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080804 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080723 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080901 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080822 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080929 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080929 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090106 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090408 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20090630 |